Forte Biosciences, Inc. (FBRX)
76.95
+0.03
(+0.04%)
USD |
NASDAQ |
Aug 24, 16:00
76.94
-0.01
(-0.01%)
After-Hours: 20:00
Forte Biosciences Net Income (Quarterly) : -23.33M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -23.33M |
| March 31, 2026 | -22.14M |
| December 31, 2025 | -24.79M |
| September 30, 2025 | -17.68M |
| June 30, 2025 | -11.25M |
| March 31, 2025 | -15.66M |
| December 31, 2024 | -7.155M |
| September 30, 2024 | -8.392M |
| June 30, 2024 | -12.51M |
| March 31, 2024 | -7.42M |
| December 31, 2023 | -5.872M |
| September 30, 2023 | -9.955M |
| June 30, 2023 | -8.896M |
| March 31, 2023 | -6.753M |
| December 31, 2022 | -4.877M |
| September 30, 2022 | -3.40M |
| June 30, 2022 | -3.035M |
| March 31, 2022 | -2.567M |
| December 31, 2021 | -3.341M |
| September 30, 2021 | -7.751M |
| Date | Value |
|---|---|
| June 30, 2021 | -5.812M |
| March 31, 2021 | -4.804M |
| December 31, 2020 | -4.576M |
| September 30, 2020 | -5.10M |
| June 30, 2020 | -34.76M |
| March 31, 2020 | -2.05M |
| December 31, 2019 | -1.564M |
| September 30, 2019 | -0.69M |
| June 30, 2019 | -0.63M |
| March 31, 2019 | -17.08M |
| December 31, 2018 | -19.60M |
| September 30, 2018 | -0.383M |
| June 30, 2018 | -16.09M |
| March 31, 2018 | -12.88M |
| December 31, 2017 | -10.84M |
| September 30, 2017 | -9.953M |
| June 30, 2017 | -9.066M |
| March 31, 2017 | -9.073M |
| June 30, 2016 | -8.042M |
| March 31, 2016 | -8.006M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 23.33M |
| EPS Diluted (Quarterly) | -0.9808 |
| Enterprise Value | 1.378B |
| Earnings Yield | -6.67% |
| Normalized Earnings Yield | -6.666 |